Literature DB >> 1672603

Required beta blocker profile in the elderly.

L H Opie1.   

Abstract

In the truly elderly, a complex balance between compensatory processes and impaired organ function allows reasonably normal physical function. It is argued that beta blockade should have certain desirable qualities to minimize any impairment of organ function, thereby upsetting the quality of life. Thus a simple pharmacokinetic pattern without hepatic metabolism is less likely to cause unexpected variation in blood levels of the beta blocking agents and to have fewer risks of interactions with other drugs including nicotine. Renal-excreted beta blockers--such as atenolol, nadolol, and celiprolol--do, however, need downward dose adjustment when the glomerular filtration rates fall. The elderly are frequently categorized as having a low renin profile, which in the view of some workers may make a vasodilatory beta blocker more desirable. Hemodynamic advantages of such agents include the prime site of attack in hypertension on the increased peripheral vascular resistance, increasingly fundamental with a prolonged duration of hypertension and therefore with the aging process. Furthermore, a normal heart rate with a sustained cardiac output may avoid symptomatic bradycardia. In the elderly, respiratory function may be impaired so that loss of elastic recoil causes elderly emphysema. A highly cardioselective beta blocker should be an advantage. Finally, minimal interference with glucose and lipid metabolism should also be desirable goals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672603     DOI: 10.1007/bf00114233

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  42 in total

1.  Changes in cardiac output with age.

Authors:  M BRANDFONBRENER; M LANDOWNE; N W SHOCK
Journal:  Circulation       Date:  1955-10       Impact factor: 29.690

Review 2.  The additional properties of beta adrenoceptor blocking drugs.

Authors:  B N Prichard; B Tomlinson
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  Comparison of the acute hemodynamic effects of intravenous celiprolol and propranolol in patients with suspected coronary disease.

Authors:  G Gensini; C Dator; P Esente; F S Caruso; T Solomon
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

4.  Effects of age and cigarette smoking on propranolol disposition.

Authors:  R E Vestal; A J Wood; R A Branch; D G Shand; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

5.  Significance of chronic sinus bradycardia in elderly people.

Authors:  N S Agruss; E Y Rosin; R J Adolph; N O Fowler
Journal:  Circulation       Date:  1972-11       Impact factor: 29.690

Review 6.  Heterogeneous pathophysiology of essential hypertension: implications for therapy.

Authors:  F H Messerli; R E Schmieder; B D Nunez
Journal:  Am Heart J       Date:  1986-10       Impact factor: 4.749

7.  The influence of beta-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia.

Authors:  K J Schlüter; W H Aellig; K G Petersen; H C Rieband; A Wehrli; L Kerp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

8.  Effect of age on plasma propranolol levels.

Authors:  R E Schneider; H Bishop; R A Yates; C P Quarterman; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

9.  Training and oxygen conductance in the elderly. II. The cardiovascular system.

Authors:  V Niinimaa; R J Shephard
Journal:  J Gerontol       Date:  1978-05

10.  Age and beta adrenoceptor-mediated function.

Authors:  N Dillon; S Chung; J Kelly; K O'Malley
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

View more
  1 in total

Review 1.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S Salpeter; T Ormiston; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.